Skip to content

Bupivacaine liposome used in knee arthroplasty for osteoarthritis to improve analgesia and reduce opioid dosage, single center, randomized, double blind, controlled trial.

Bupivacaine liposome used in knee arthroplasty for osteoarthritis to improve analgesia and reduce opioid dosage, single center, randomized, double blind, controlled trial.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076174
Enrollment
Unknown
Registered
2023-09-26
Start date
2023-10-07
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthrosis

Interventions

Group B:Give adductor canal block with Bupivacaine liposome
Group R:Give adductor canal block with Ropivacaine

Sponsors

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Selection criteria (1) Patients with osteoarthrosis, patients undergoing elective knee replacement (2) 18-70 years old (3)BMI:18-30kg/m2 (4)ASA classification I-III Be able to understand and score VAS, sign informed consent form voluntarily, and be willing to comply with the requirements of the test plan.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) contraindications for bupivacaine; History of allergic or specific reactions to amide local anesthetics (2) Body mass index > 30 kg/m2 (3) Patients with severe heart, lung and renal insufficiency, complicated with various chronic diseases and unable to tolerate surgical anesthesia and mental illness; (4) Those who have a history of alcoholism, opioid allergy or abuse of such drugs; (5) Uncontrolled hypertension and diabetes; (6) emergency surgery patients; (7) Pregnant or lactating women; (8) People with a history of nervous system diseases or unable to communicate normally; Other circumstances that the researcher thinks are not suitable for the group.

Design outcomes

Primary

MeasureTime frame
Remifentanil dosage;VAS score (resting);VAS score (moving);

Secondary

MeasureTime frame
Sufentanil dosage;Postoperative analgesia satisfaction;

Countries

China

Contacts

Public ContactHe Keqiang

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

doctorhector@ustc.edu.cn+86 139 6500 8903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026